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Objectives The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-
segment elevation myocardial infarction (STEMI).
Background Given the high thrombotic risk of patients with STEMI, greater platelet inhibition may improve outcome in those
patients receiving percutaneous coronary intervention (PCI). Although observational data suggest that pretreat-
ment with a 600-mg clopidogrel loading dose may be more effective than the 300-mg regimen in primary PCI,
this hypothesis has never been tested in a randomized study.
Methods A total of 201 patients undergoing primary PCI for STEMI randomly received a 600-mg (n  103) or 300-mg
(n  98) clopidogrel loading dose before the procedure. The primary endpoint was the evaluation of the infarct
size, defined as the area under the curve of cardiac markers.
Results Infarct size was significantly lower in the high-dose regimen: median creatine kinase-myocardial band 2,070
ng/ml (interquartile range [IQR]: 815 to 2,847 ng/ml) versus 3,049 ng/ml (IQR: 1,050 to 7,031 ng/ml) in the
300-mg group, p  0.0001; troponin-I 255 ng/ml (IQR: 130 to 461 ng/ml) versus 380 ng/ml (IQR: 134 to
1,406 ng/ml), p  0.0001. In the 600-mg arm, Thrombolysis In Myocardial Infarction flow grade 3 after PCI
was less frequent (5.8% vs. 16.3%, p  0.031), left ventricular ejection fraction at discharge was improved
(52.1  9.5% vs. 48.8  11.3%, p  0.026), 30-day major adverse cardiovascular events were fewer (5.8% vs.
15%, p  0.049), and bleeding/entry site complications were not increased (secondary endpoints).
Conclusions In STEMI patients, pre-treatment with a 600-mg clopidogrel loading dose before primary PCI was associated with
a reduction of the infarct size compared with a 300-mg loading dose, as well as with improvement of angio-
graphic results, residual cardiac function, and 30-day major adverse cardiovascular events; further studies are
warranted to evaluate impact of such strategy on survival. (J Am Coll Cardiol 2011;58:1592–9) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.044d
pTherapy with clopidogrel represents a cornerstone in pa-
tients undergoing percutaneous coronary intervention
(PCI), including primary intervention for ST-segment ele-
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October 4, 2011:1592–9 High Clopidogrel Loading Dose in Primary PCIwith STEMI have a high thrombotic risk, thus greater platelet
inhibition at the time of PCI might improve the angio-
graphic results and translate into lower periprocedural isch-
emic events. Furthermore, the adequacy of platelet response
to standard doses of clopidogrel, mainly in the setting of
acute coronary syndromes, remains a debated issue in
interventional cardiology (5–8). Previous randomized stud-
ies demonstrated in patients undergoing nonurgent PCI a
significant reduction of early cardiac events after pre-
treatment with a 600-mg compared with a 300-mg clopi-
dogrel loading dose (9,10). Recent observational data sug-
gest that in patients with STEMI treated with primary PCI,
the use of a 600-mg clopidogrel loading dose is associated
with improvement of procedural angiographic endpoints
and safely decreases the rate of adverse event compared with
the 300-mg regimen (11–14); to date, no study evaluated
this approach in a prospective, randomized protocol. Thus,
the ARMYDA (Antiplatelet Therapy for Reduction of
Myocardial Damage During Angioplasty) study group de-
signed the randomized ARMYDA-6 MI to evaluate in the
setting of urgent PCI for STEMI the impact of pre-
treatment with a 600-mg versus a 300-mg clopidogrel
loading dose on efficacy and safety outcomes.
Methods
Study population and design. ARMYDA-6 MI is an
international, multicenter, randomized, prospective trial
performed at 5 institutions (Campus Bio-Medico Univer-
sity of Rome; Semmelweis University Heart Center of
Budapest; Clinical Center of Serbia, Medical School of
Belgrade; Cardiovascular Center, OLV Hospital of Aalst;
Figure 1 Design of ARMYDA-6 MI Trial
ASA  aspirin; CK-MB  creatine kinase-myocardial band; GP  glycoprotein; Hb
adverse cardiovascular event(s); MI  myocardial infarction; PCI  percutaneousVito Fazzi Hospital of Lecce).
Consecutive patients with STEMI
undergoing primary PCI were
included; STEMI was defined as
symptoms of acute myocardial
ischemia lasting 30 min with
symptom onset 12 h, and ST-
segment elevation0.1 mV in at
least 2 leads on the electrocardio-
gram (15). Exclusion criteria
were rescue PCI after thrombol-
ysis, cardiogenic shock, platelet
count 70  109/l, or treatment
ith clopidogrel within 10 days
rom randomization. A total of
01 patients fulfilling the enroll-
ent criteria were randomized to
eceive a 600-mg (n  103) or 300-mg (n  98) loading
ose of clopidogrel at the time of the first medical contact at
he center performing primary angioplasty (i.e., in the
mergency department before sending patient to the cath-
terization lab) (Fig. 1). Eligible patients were assigned to
00 or 300 mg clopidogrel using an electronic spreadsheet
ndicating the group assignment by random numbers; ran-
omization blocks were created and distributed to the 5
enters. Physicians performing the follow-up assessment
ere not aware of the randomization assignment.
All interventions were performed using the standard
echnique. All patients received an intravenous dose of 500
g aspirin and unfractionated heparin (70 IU/kg body
eight) before intervention. Thrombus aspiration and gly-
Abbreviations
and Acronyms
AUC  area under the
curve
CK-MB  creatine kinase-
myocardial band
IQR  interquartile range
MACE  major adverse
cardiovascular event(s)
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
oglobin; LVEF  left ventricular ejection fraction; MACE  major
ry intervention; TIMI  Thrombolysis In Myocardial Infarction; Tn  troponin. hem
corona
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High Clopidogrel Loading Dose in Primary PCI October 4, 2011:1592–9coprotein IIb/IIIa inhibitors were used at the operator’s
discretion. After the intervention, in all patients, aspirin
(100 mg/day) was indefinitely continued, and clopidogrel
was prescribed at the conventional maintenance dose of 75
mg/day from the day after PCI up to 1 year.
Blood samples were collected before the PCI and at 4,
8, 12, 24, 36, 48, and 72 h after the procedure to measure
creatine kinase-myocardial band (CK-MB) (mass),
troponin-I (mass), and hemoglobin levels. One-month
clinical follow-up was performed by office visit of all
study patients. Each patient gave informed consent to
participate in the study. The study was approved by the
institutional review boards of the participating institu-
tions. The present study was not supported by any
industry sponsorship.
Endpoint definitions. The primary endpoint of the
ARMYDA-6 MI trial was the evaluation of the infarct size,
defined as CK-MB and troponin-I area under the curve
(AUC), calculated by the linear trapezoidal method (16). If
baseline or 72-h values were missing, the value was set to 0,
whereas missing intermediate values were substituted by
linear interpolation. For patients dying in the first 72 h after
enrollment, the AUC was set as the largest AUC recorded
in the study.
The following secondary endpoints were investigated:
1. Prevalence of Thrombolysis In Myocardial Infarction
(TIMI) flow grade 1 at the diagnostic coronary an-
giography before PCI and of TIMI flow grade 3 after
PCI (17).
. Left ventricular ejection fraction by transthoracic echo-
cardiography at discharge.
. The incidence of major adverse cardiovascular events
(MACEs) (e.g., death, repeat myocardial infarction,
target vessel revascularization, stroke) at 30 days. Rein-
farction (18) was defined as recurrent symptoms with: a)
re-elevation of CK-MB by at least 33% (if 2 times
normal) or 100% (if 2 times normal) from the preced-
ing nadir at 24 h after PCI; b) new Q waves or
re-elevation of CK-MB to 3 times normal at 24 h to
discharge; and/or c) new Q waves or re-elevation of
CK-MB to 2 times normal after discharge. Target
vessel revascularization included ischemia-driven bypass
surgery or repeat PCI of the infarct-related artery;
. Occurrence of bleeding/entry site complications: a) 30-
day major bleeding defined as intracranial bleeding or
clinically overt bleeding associated with a decrease in
hemoglobin of 5 g/dl according to the TIMI criteria
(19); b) 30-day minor bleeding (clinically overt hemor-
rhage associated with a decrease in hemoglobin of 5
g/dl) (19); and/or c) hematoma 10 cm, pseudoaneu-
rysm, or arteriovenous fistula.
tatistics. Based on previous evidence of primary PCI
utcomes (20), we assumed that an infarct size determined
y the CK-MB AUC of 5,000 ng/ml with an SD of 3,500
g/ml could be expected in the 300-mg group. Predicting a0% reduction in the infarct size in the 600-mg group, a
inimum total number of 182 patients was needed to
chieve an 80% power with a 2-sided  value of 0.05 to
detect such a difference. Anticipating a 10% dropout rate of
patients in whom complete serial measurements of CK-MB
would not be obtained, enrollment was set to at least 200
patients.
Continuous variables in the 2 arms were compared by t
test for normally distributed values (as assessed by
Kolmogorov-Smirnov test); otherwise, the Mann-Whitney
U test was used. Proportions were compared by the Fisher
exact test when the expected frequency was 5; otherwise
the chi-square test was applied. Event-free survival analysis
was performed by the Kaplan-Meier method with log-rank
test group comparison. Normally distributed variables were
expressed as mean SD, whereas non-normally distributed
variables were expressed as median and interquartile range.
A p value 0.05 (2-tailed) was considered significant.
Analysis was performed with SPSS version 12.0 (SPSS Inc.,
Chicago, Illinois) software.
Results
Study population. Clinical and procedural variables were
not different in the 2 arms and are shown in Tables 1 and 2,
respectively; symptoms-to-balloon time were also similar
(600 mg: 283  183 min vs. 300 mg: 288  223 min; p 
0.86), as well as clopidogrel load-to-balloon time (35  34
min vs. 39  41 min; p  0.45). Procedure success was
chieved in all patients. Four of 103 patients (3.9%) in the
00-mg group and 5 of 98 (5.1%) in the 300-mg group had
o-reflow phenomenon (p  0.94), defined as a decrease of
IMI flow grade 1 after initial successful reperfusion of
he culprit artery not due to abrupt vessel closure, spasm,
issection, or significant residual stenosis.
rimary endpoint. Infarct size, measured by AUC of
ardiac markers, was significantly reduced in patients ran-
omized to the high-dose clopidogrel regimen: median
K-MB, 2,070 ng/ml (interquartile range [IQR]: 815 to
,847 ng/ml) versus 3,049 ng/ml (IQR: 1,050 to 7,031
g/ml) in the 300-mg group, p  0.0001; troponin-I, 255
ng/ml (IQR: 130 to 461 ng/ml) versus 380 ng/ml (IQR: 134
to 1,406 ng/ml), p  0.0001 (Fig. 2).
Secondary endpoints. Overall, 21.4% of patients (22 of
103) in the 600-mg arm versus 12.2% (12 of 98) in the
300-mg arm had TIMI flow grade 1 at the diagnostic
coronary angiography before PCI (p  0.12); high-dose
clopidogrel loading was associated with significantly lower
incidence of TIMI flow grade 3 after the intervention
(5.8%, 6 of 103 patients, vs. 16.3%, 16 of 98; p  0.031)
(Table 2). Left ventricular ejection fraction early after PCI
was similar in the 2 arms (43.2  10.4% vs. 41.8  14.1%;
p  0.42), but was higher at discharge in the 600-mg
regimen (52.1  9.5% vs. 48.8  11.3%; p  0.026).
The incidence of 30-day MACE was reduced in the
600-mg group: 5.8% (6 of 103 patients) versus 15.0% (15 of
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October 4, 2011:1592–9 High Clopidogrel Loading Dose in Primary PCI98) in the 300-mg group (p  0.049). Individual compo-
ents of this composite endpoint are shown in Table 3; in
articular, in the high-dose clopidogrel regimen, 4 patients
ied (vs. 7), 1 required target vessel revascularization (vs. 7),
nd 1 had reinfarction (vs. 5). Target vessel revascularization
ithin 30 days due to stent thrombosis occurred in 1 patient
n the 600-mg arm and in 4 patients in the 300-mg arm;
arget vessel revascularization in the remaining 3 patients in
he lower dose regimen group was performed in 2 because of
ecurrent angina with angiographic evidence of coronary
hrombosis distal to the stented segment and in 1 patient
ecause of hemodynamic impairment associated with low
istal flow.
Definite stent thrombosis by the Academic Research
onsortium definition (21) occurred in 1 patient in the
00-mg group versus 2 in the 300-mg group, whereas
efinite or probable stent thrombosis occurred in 1 versus 4,
espectively. MACE-free survival curves in the 2 arms at 1
Clinical Characteristics in the 2 ArmsTable 1 Clinical Characteristics in the 2 Arms
600-mg
Clopidogrel
(n  103)
300-mg
Clopidogrel
(n  98) p Value
Age, yrs 62 11 65 14 0.09
Male 73 (71) 60 (61) 0.20
Systemic hypertension 64 (62) 65 (66) 0.64
Diabetes mellitus 22 (21) 29 (30) 0.24
Hyperlipidemia 51 (50) 45 (46) 0.71
Active smokers 58 (56) 42 (43) 0.08
Previous myocardial infarction 8 (7) 12 (12) 0.41
Previous percutaneous coronary
intervention
5 (5) 10 (10) 0.24
Previous bypass surgery 1 (1) 0 (0) 0.98
Body mass index, kg/m2 27.8 5.5 27.0 5.3 0.30
Chronic renal failure 9 (9) 7 (7) 0.88
Serum creatinine, mg/dl 1.04 0.74 1.08 1.40 0.80
Hemoglobin, g/dl 14.2 1.4 13.9 1.8 0.19
Symptoms-to-balloon time, min 283 183 288 223 0.86
First medical contact-to-
randomization time
20 9 21 11 0.48
Clopidogrel load-to-balloon
time, min
35 34 39 41 0.45
Site of infarction
Anterior, anterolateral,
anteroseptal
43 (42) 40 (41) 0.99
Inferior, inferoposterior,
inferolateral
60 (58) 58 (59) 0.99
Killip class III–IV 22 (21) 23 (24) 0.85
LVEF (acute phase), % 43.2 10.4 41.8 14.1 0.42
Medical therapy
Aspirin 103 (100) 98 (100) —
Statins 88 (85) 79 (81) 0.75
ACE inhibitors/sartans 62 (60) 56 (57) 0.77
Beta-blockers 68 (66) 63 (64) 0.91
Proton pump inhibitors 82 (80) 78 (80) 0.86
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction.onth are reported in Figure 3.The safety endpoint did not differ in the 600- and
300-mg arms (Table 3): major bleeding at 1 month occurred
in 1.9% versus 2.0% of patients, nonentry site minor
bleeding in 7.8% versus 6.1%, and entry site complications
in 2.9% versus 3.1%. No patient had post-procedure throm-
bocytopenia with platelet count 70  109/l.
Discussion
This randomized study demonstrates that pre-treatment
with a 600-mg clopidogrel loading dose before primary PCI
compared with the 300-mg regimen decreases the infarct
size (as determined by both CK-MB and troponin-I release)
in patients with STEMI. Pre-treatment with a higher
clopidogrel dose may also improve TIMI flow at the end of
the procedure and left ventricular function at discharge and
may reduce clinical events at 1 month.
There is a strong rationale for using an “aggressive”
antiplatelet strategy in patients with STEMI undergoing
primary PCI; in fact, the time from administration of
antiplatelet drugs to intervention is reduced in those pa-
tients, and there is increased platelet activation (22), which
may limit the effects of antiplatelet agents, especially at
standard doses (23). In patients with STEMI, a correlation
between platelet reactivity and the extent of myocardial
necrosis has also been demonstrated (24), and platelet
reactivity on admission significantly predicts the risk of
MACE during follow-up after PCI (22); moreover, platelet
Angiographic/Procedural CharacteristicsTable 2 Angiographic/Procedural Characteristics
600-mg
Clopidogrel
(n  103)
300-mg
Clopidogrel
(n  98) p Value
Type of vessel
Left anterior descending 40 (38) 38 (36) 0.93
Left circumflex 31 (29) 34 (32) 0.73
Right coronary artery 33 (31) 32 (31) 0.96
Saphenous vein graft 2 (2) 1 (1) 0.99
Multivessel coronary disease 37 (36) 42 (43) 0.39
Multivessel PCI 3 (3) 7 (7) 0.29
Approach
Femoral 74 (72) 72 (74) 0.92
Radial 29 (28) 26 (26) 0.92
Type of intervention
Balloon only 1 (1) 1 (1) 0.50
Stent 102 (99) 97 (99) 0.50
Use of drug-eluting stents 11 (11) 19 (19) 0.13
Total stent length, mm 22.0 6.2 20.9 7.9 0.27
Stent diameter, mm 3.1 0.6 3.1 0.5 0.98
No. of stents per patient 1.38 0.98 1.29 0.59 0.43
Direct stenting 42 (41) 37 (38) 0.77
Thrombus aspiration 19 (18) 14 (14) 0.55
Glycoprotein IIb/IIIa inhibitors 58 (56) 48 (49) 0.37
Intra-aortic balloon pump 1 (1) 2 (2) 0.97
TIMI flow pre-PCI 1 22 (21) 12 (12) 0.12
TIMI flow post-PCI 3 6 (6) 16 (16) 0.031Values are n (%) or mean  SD.
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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the intervention (22), and platelet-mediated impairment of
microcirculation may advance the reperfusion injury of the
area at risk (25,26). In patients with STEMI undergoing
primary PCI, an early further increase in platelet reactivity
has been observed after the procedure despite a 300-mg
clopidogrel loading (27), reflecting procedural platelet acti-
vation, enhanced platelet consumption, and microparticle
formation; of note, the degree of this post-PCI increase in
platelet reactivity affects the subsequent clinical outcome
(27). Finally, delays in drug absorption and/or metabolism
in the acute infarction setting might further affect pharma-
cokinetics and pharmacodynamics of oral antiplatelet agents
(13). Thus, platelet inhibition represents an important
target of treatment beyond pure mechanical intervention
because patients with STEMI, in the context of high
thrombotic and inflammatory activation, are at higher risk
of ischemic events and may derive the greatest benefit from
a strategy of more intense platelet suppression. Use of
newer, more potent antiplatelet drugs (e.g., prasugrel, ti-
Ischemic and Safety Outcomes in the 2 ArmsTable 3 Ischemic and Safety Outcomes in the 2 Arms
600-mg
Clopidogrel
(n  103)
300-mg
Clopidogrel
(n  98) p Value
30-day MACE 6 (5.8) 15 (15.0) 0.049
Individual components
Death 4 (3.9) 7 (7.1) 0.48
Reinfarction 1 (0.98) 5 (5.1) 0.19
TVR 1 (0.98) 7 (7.1) 0.06
Stroke 0 1 (1.0) 0.98
Death  reinfarction 5 (4.9) 12 (12.2) 0.10
Death  reinfarction  stroke 5 (4.9) 13 (13.2) 0.07
Death  reinfarction  TVR 6 (5.8) 14 (14.2) 0.08
Definite or probable stent thrombosis 1 (0.98) 4 (4.1) 0.34
Safety endpoint
30-day major bleeding 2 (1.9) 2 (2.0) 0.65
30-day minor bleeding 8 (7.8) 6 (6.1) 0.86
Entry-site complications 3 (2.9) 3 (3.1) 0.72
Figure 2 Primary Study Endpoint
Infarct size in the 2 arms by area under the curve of creatine kinase-myocardial baValues are n (%).
MACE  major adverse cardiovascular event(s); TVR  target vessel revascularization.cagrelor) instead of clopidogrel significantly decreased the
incidence of ischemic events in patients with acute coronary
syndromes undergoing PCI, also including those with STEMI
(28–30), but at the price of increased bleeding events, which
may in turn worsen the prognosis (31,32). However, a direct
comparison of prasugrel and pretreatment with 600 mg clopi-
dogrel in clinical trials in patients undergoing PCI has never
been performed (33).
A 600-mg clopidogrel load produces a faster antiplatelet
effect than the 300-mg dose, with a maximal platelet
inhibition achieved 2 h after drug administration (vs. 12 h)
(34,35); moreover, the higher dose regimen significantly
reduced the rate of nonresponders in patients treated with
PCI from 28% to 8% (36). Previous randomized studies
demonstrated that pre-treatment with a 600-mg clopidogrel
loading dose improves the clinical outcome in patients
undergoing nonurgent PCI. In particular, the 600-mg
regimen was associated in the ARMYDA-2 trial (9) with a
52% relative risk reduction of 30-day adverse events com-
pared with the 300-mg dose, and this benefit was mainly
driven by prevention of periprocedural myocardial infarc-
tion; the higher regimen was also superior for early ischemic
endpoints in a randomized study specifically including
patients with non–ST-segment elevation acute coronary
syndrome (10). More recently, in a prespecified subanalysis
of the CURRENT–OASIS 7 (Clopidogrel Optimal Load-
ing Dose Usage to Reduce Recurrent Events–Optimal
Antiplatelet Strategy for Interventions 7) trial (37), the
combination of a 600-mg clopidogrel loading dose followed
by a 150-mg daily dose given for 7 days significantly
decreased the incidence of MACEs at 1 month versus the
conventional strategy (300-mg loading dose followed by 75
mg/day) in patients with acute coronary syndrome under-
going PCI. Improvement of endothelial function and re-
duction of inflammation might also be associated with the
benefit of the higher clopidogrel maintenance dose beyond
the expected stronger platelet inhibition (38). To date, only
observational investigations (11–14) evaluated the compar-
ison of a 600-mg versus a 300-mg clopidogrel loading dose
K-MB) (A) and troponin-I (B).nd (Cin patients with STEMI undergoing PCI; in those studies,
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outcome, with lower 30-day rates of the composite end-
points including death, myocardial infarction, stroke, and
urgent revascularization (11), as well as mortality and stent
thrombosis (13) and fewer cardiac events at 1 year (14). Of
Figure 3 MACE-Free Survival Curves at 1 Month in the
600-mg Versus 300-mg Clopidogrel Arms
TVR  target vessel revascularization; other abbreviations as in Figure 1.note, the latest published guidelines on myocardial revascu-larization (39) recommend a 600-mg clopidogrel loading
dose in the context of primary PCI for STEMI, with Class
of Recommendation I and Level of Evidence: C, given the
absence of randomized studies.
The multicenter ARMYDA-6 MI trial demonstrates in a
randomized protocol that a 600-mg clopidogrel loading
dose compared with the 300-mg regimen significantly
decreases the extent of the myocardial necrosis after primary
PCI. As observed in this study, this may be a consequence
of higher patency rates of the infarct-related artery at the
time of the intervention, as well as of achieving a better
coronary flow after the procedure. When PCI is performed
very early after clopidogrel administration, as typically
occurs in the setting of STEMI (a mean of 36 min in our
study), pre-treatment with a 600-mg loading dose allows
stronger platelet inhibition at the time of the procedure.
This may translate into a reduction of the thrombotic
burden, reduced platelet-related intraprocedural events, de-
creased reperfusion injury, and subsequent reduction of the
infarct size; the latter in ARMYDA-6 MI was paralleled by
improved left ventricular function at discharge. A more
intense periprocedural platelet inhibition might also have a
favorable impact on the clinical prognosis in patients un-
dergoing primary PCI, as suggested by the reduction of
30-day MACE with the 600-mg clopidogrel regimen,
which was mainly driven by prevention of early reinfarction
and urgent target vessel revascularization. No excess bleed-
ing complications were observed with the higher loading
dose, and this confirms the results of a recent post hoc
analysis from the HORIZONS-MI (Harmonizing Out-
comes With Revascularization and Stents in Acute Myo-
cardial Infarction) trial (13).
Study limitations. ARMYDA-6 MI was not powered for
the evaluation of clinical endpoints; thus, the lower inci-
dence of adverse events at 1 month in the 600-mg arm
(secondary endpoint) needs to be confirmed in larger ran-
domized studies. We measured the infarct size by AUC of
CK-MB and troponin-I; although this is considered a
reliable measure of the extent of the infarct, evaluation of
this parameter by magnetic resonance imaging would have
been more accurate. Further investigation is warranted to
evaluate the impact of the observed improvement in angio-
graphic results, infarct size, and cardiac function by high-
dose clopidogrel on survival.
Conclusions
ARMYDA-6 MI demonstrates that a 600-mg clopidogrel
loading dose is safe and more effective than the 300-mg
regimen in the context of primary PCI for STEMI. The
results provide a randomized contribution supporting the
use of 600 mg clopidogrel as the loading dose of choice in
these patients. Although prasugrel and ticagrelor have a
higher recommendation grade (I B) (39) in patients under-
going primary PCI for STEMI, our results may have
relevance with regard to practice patterns because clopi-
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High Clopidogrel Loading Dose in Primary PCI October 4, 2011:1592–9dogrel is nevertheless still widely used in those patients,
especially in the presence of high bleeding risk features, such
as bleeding-prone gastrointestinal or genitourinary lesions,
older age, low body weight, and previous stroke.
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